Eylea 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Eylea
|
Active substance |
aflibercept
|
Therapeutic area (MeSH) |
|
Procedure number |
EMEA/H/C/002392/II/0068
|
Regulatory outcome |
Variation
|
DHPC type |
Adverse event
|
Human ATC code |
S01LA05
|
Dissemination date |
15/04/2021
|